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Mexico is still in the growing phase of the epidemic of coronary heart disease (CHD), with
mortality increasing by 48% since 1980. However, no studies have analyzed the drivers of
these trends. We aimed to model CHD deaths between 2000 and 2012 in Mexico and to
quantify the proportion of the mortality change attributable to advances in medical treat-
ments and to changes in population-wide cardiovascular risk factors.
Methods
We performed a retrospective analysis using the previously validated IMPACT model to
explain observed changes in CHD mortality in Mexican adults. The model integrates nation-
wide data at two-time points (2000 and 2012) to quantify the effects on CHD mortality attrib-
utable to changes in risk factors and therapeutic trends.
Results
From 2000 to 2012, CHD mortality rates increased by 33.8% in men and by 22.8% in
women. The IMPACT model explained 71% of the CHD mortality increase. Most of the mor-
tality increases could be attributed to increases in population risk factors, such as diabetes
(43%), physical inactivity (28%) and total cholesterol (24%). Improvements in medical and
surgical treatments together prevented or postponed 40.3% of deaths; 10% was attributable
to improvements in secondary prevention treatments following MI, while 5.3% to community
heart failure treatments.
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Conclusions
CHD mortality in Mexico is increasing due to adverse trends in major risk factors and subop-
timal use of CHD treatments. Population-level interventions to reduce CHD risk factors are
urgently needed, along with increased access and equitable distribution of therapies.
Introduction
Coronary heart disease (CHD) remains as one of the most important worldwide mortality
causes. Currently, most developed countries are experiencing a decrease in CHD mortality,
and some have reduced their rates by 50%, compared to the 1970s [1]. The reasons for these
decreases are variable, yet, they have been attributed to declines in major risk factors and
advances in medical and surgical treatment [2, 3]. In low and middle-income countries, the
behavior of the CHD epidemic differs, while CHD mortality in some countries is decreasing,
many other countries are still experiencing increases in CHD mortality [4]. Mexico, an upper
middle-income country with 129 million inhabitants, is one of the countries that are still in the
rising phase of the CHD epidemic [5].
In the past century, Mexico was characterized as a country of low CHD mortality. In 1980,
the age-standardized mortality rate per 100,000 inhabitants were 55.6 and 33.8 for men and
women, respectively [6]. However, between 1980 and 2010, substantial changes in the country
led to a 48% increase in CHD mortality [7]. An explosive increase in obesity and diabetes has
been proposed as the main factor for CHD mortality increase [8]. Simultaneously, the country
experienced a reduction in smoking rates, from 25.9% in 1980 to 10% in 2012 [9], which
should have led to a reduction in coronary morbidity and mortality. Also, since 2004, access to
CHD clinical and surgical treatments increased under Seguro Popular, a health insurance pro-
gram to provide access to packages of health services for people without access to social secu-
rity services [10, 11]. Treatments such as thrombolysis, coronary-artery bypass grafting
(CABG), coronary angioplasty, ACE inhibitors and statins are now more commonly used and
available for more people [12, 13]. While the rises in CHD mortality in Mexico are clear, we
still lack an analysis of the fundamental causes of these changes [14].
In the last decades, various models have been developed to measure the contribution of risk
factors and treatment changes in CHD mortality [2, 3, 15, 16]. These models use up-to-date
scientific evidence to estimate the contribution of population changes in risk factors and con-
sider the accessibility and effectiveness medical and surgical treatments, to changes in CHD
mortality [17]. The IMPACT model has been implemented in United Kingdom, the United
States, New Zealand, Syria, Tunisia and China among others [3, 16, 18–21]. IMPACT studies
in high-income countries concluded that CHD mortality reductions were largely attributable
to improvements in risk factors, such as obesity and hypertension, which explained from 44%
of the reduction in the United States [3] to 76% in Finland [22]. IMPACT has also been imple-
mented in low and middle-income countries that were experiencing increases in CHD mortal-
ity rates, such as Tunisia [18] and Syria [23], where risk factors explained more than 60% of
the change.
To our knowledge, no study has estimated the contribution of risk factors and medical and
surgical treatments on CHD mortality in Mexico. This information is key to identify potential
targets for public and medical policy aiming to reduce the burden of CHD. We aimed quantify
what proportion of the CHD mortality change between 2000 and 2012 that is attributable to
advances in medical and surgical treatment and changes in population-wide cardiovascular
risk factors using the IMPACT model.
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basesdedatos/bdc_egresoshosp_gobmx.html (4)
Treatments: Mexican Ministry of Health and
National Registry of Acute Coronary Syndromes
(RENASICA). Data is only available upon request
from the RENASICA Executive Committee: http://
www.renasica.mx/contacto.html (5) Risk factors:
National Nutrition and Health Surveys (ENSANut)
https://ensanut.insp.mx/ In the case National
Registry of Acute Coronary Syndromes, the data
are available upon reasonable request from the
RENASICA Executive Committee. The authors
confirm that they had no special access privileges
in accessing these data sets. Contact information:
Dr. Carlos Martı́nez (RENASICA Executive
Committee), email: martinez@renasica.mx,
info@renasica.mx and publicaciones@renasica.mx
The rest of the datasets are publicly available and
anonymous.
Funding: Carmen Arroyo-Quiroz received support
from CONACyT’s Scholarship Program for Doctoral
Studies. Tonatiuh Barrientos-Gutierrez received
support from Harvard University through the Lown
Scholar’s program (https://www.hsph.harvard.edu/
lownscholars/scholars/). The funders had no role
in the study design or the analysis and
interpretation of the data. All authors and their
institutions reserve intellectual freedom from the
funders.
Competing interests: The authors have declared
that no competing interests exist.
Material and methods
The IMPACT policy model was used in this study to quantify the effects on CHD mortality
attributable to variations in each population risk factors and treatment modalities between
2000 and 2012 [2, 17, 23–26]. The model methodology has been described in detail elsewhere
[3, 16, 17, 23]. Briefly, the IMPACT model is used to estimate the number of coronary heart
disease (CHD) death change attributable to changes in specific cardiac interventions, treat-
ments, or risk factors. In this study, adult data including: (1) number of CHD patients, (2) use
of specific medical and surgical treatments, (3) effectiveness of specific treatments for CHD,
(4) population trends of major cardiovascular risk factors (smoking, total cholesterol, hyper-
tension, obesity, and diabetes), were incorporated into the model [2, 3, 16, 25].
Data sources
National information on mortality, morbidity, hospital discharges, medical and surgical treat-
ments, and cardiovascular risk factors was obtained for the years 2000 and 2012. All data are
national and grouped by age and sex. Data used are described in detail in S1 Appendix, briefly,
we used four data sources:
• Population size: Mexican National Population Council (CONAPO) [27]
• Mortality: Mexican Ministry of Health Information System [7, 28]
• Number of patients: Mexican Ministry of Health Information System [29]
• Treatments: Mexican Ministry of Health and National Registry of Acute Coronary Syn-
dromes (RENASICA) [13, 30, 31]
• Risk factors: National Nutrition and Health Surveys (ENSANut) [32, 33]
In the case National Registry of Acute Coronary Syndromes, the data are available only
upon request from the RENASICA Executive Committee, the rest of the datasets are publicly
available and anonymous. We limited our CHD mortality analysis to the 2000 to 2012 period,
since 2012–2013 was the last wave of RENASICA data.
Deaths prevented or postponed (DPP)
The primary output was Deaths Prevented of Postponed (DPP) for CHD. DPP represents the
difference between the 2012 expected CHD deaths, calculated assuming no change in the dis-
tribution of risk factors and medical and surgical treatments available in 2000, to the CHD
mortality observed in 2012. Mortality rates from CHD were calculated using the underlying
cause of death: International Classification of Diseases (ICD) -10 codes I20-I25 [3]. We used
demographic data obtained from the Mexican National Population Council (CONAPO) and
mortality data for adults aged 25 years and older from the Health Information System from
the Mexican Health Ministry to calculate the CHD age- sex-group-specific mortality rates in
2000 and 2012. The expected number of CHD deaths in 2012 was calculated by multiplying
age-sex group-specific mortality rates in 2000 by the corresponding population size of each
10-year age-sex stratum in 2012 [2, 3, 16, 25, 26]. A positive DPP implies a decrease in
observed mortality, relative to the expected mortality, while a negative DPP implies an increase
in observed relative to expected mortality.
DPP ¼ Expected mortality2012  Observed mortality2012
The obtained DPP is the number of deaths to be explained by the model, this was achieved
thorough the contribution of DPPtreatment, which represents de DPP that is attributable to
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changes in medical and surgical treatments, and DPPrisk, that represents the DPP attributable
to changes in risk factors.
DPP ¼ Expected mortality2012  Observed mortality2012 ¼ DPPtreatment þ DPPrisk þ e
Where e represents an error term that captures the change that is not explained by our
model. In the next sections we will explain how every DPP was calculated.
Mortality changes attributable to treatment uptake
The first step in the estimation of DPP is to calculate DPPtreatment, which is a combination of
the individual DPPtreatment as a result of each intervention/ therapy in each group of patients in
2012, stratified by age and sex. To achieve this, we specified relevant treatments for each of the
nine mutually exclusive patient groups [3, 17, 34, 35]:
• Patients treated in hospital for myocardial infarction (ST-elevation myocardial infarction
and non-ST elevation acute coronary syndrome)
• Patients admitted to the hospital with unstable angina
• Community-dwelling patients who have survived a myocardial infarction (MI) for over a year
• Patients who have undergone a revascularization procedure up to and including the years
1980 and 2012: Coronary artery bypass grafting (CABG), or a percutaneous coronary inter-
vention (PCI)
• Community-dwelling patients with stable coronary artery disease
• Patients admitted to hospital with heart failure (due to CHD)
• Community-dwelling patients with heart failure (due to CHD)
• Hypercholesterolemic subjects without CHD eligible for cholesterol-lowering therapy such
as statins
• Hypertensive individuals without CHD eligible for anti-hypertensive therapy
To obtain the DPPtreatment for an specific group of patients and therapy we used the number
of people in each diagnostic group of patients in 2000 and then it was multiplied by the pro-
portion of patients who received a particular treatment, by their case fatality rate over a 1-year
period, and by the relative reduction in the 1-year case fatality rate reported for that treatment
in the largest and most recent meta-analysis [3, 17, 36, 37] (S2 Appendix).
For example, in 2012, 10,752 men aged 45 to 54 were hospitalized with myocardial infarc-
tion (MI). The expected age-specific 1-year case-fatality rate was 5.4%. 79% were prescribed
acetylsalicylic acid, with an expected mortality reduction of 15%. The number of DPP was
then calculated as:
DPPMI  ASA ¼ 10 752� 79%� 15%� 5:4% ¼ 69 deaths prevented or postponed
This process was replicated for every sex-age group, patient group, and therapy. Some spe-
cial considerations were made to these initial calculations. We assumed that the proportion of
treated patients actually taking therapeutically effective levels of medication (adherence), was
100% among hospitalized patients, 70% among symptomatic patients in the community, and
50% among asymptomatic patients in the community [3, 25].
In the case of individual patients that were receiving multiple treatments, we applied the
Mant and Hicks cumulative-relative benefit approach to estimate the potential effect on the
PLOS ONE Explaining the increment in coronary heart disease mortality in Mexico between 2000 and 2012
PLOS ONE | https://doi.org/10.1371/journal.pone.0242930 December 3, 2020 4 / 15
relative decrease in the case fatality rate for those patients [3, 36–39]
Relative Benefit ¼ 1   ½ð1  relative reduction in case fatality rate for treatment AÞ
� ð1  relative reduction in case fatality rate BÞ � . . . . . .
Potential overlaps between different groups of patients were detected and adjustments were
made to prevent double-counting (e.g., 50% of patients having CABG surgery had previous
myocardial infarction) (S3 Appendix) [3, 17, 25]. Briefly, we subtracted the DPPs calculated in
the treatment component from the DPPs calculated in the risk factors component. Additional
assumptions are listed in S3 Appendix.
After carrying out all these calculations, we combined the DPPtreatment for every patient
group and treatment until we obtained a single DPPtreatment by age-sex group that considered
all groups of patients and possible therapies.
Mortality changes attributable to risk factor changes
The second component of the IMPACT model includes estimating the number of DPPrisk for
CHD due to changes in the cardiovascular risk factors for every age-sex group. We included
six major cardiovascular risk factors in the model: smoking, physical inactivity, body mass
index (BMI), systolic blood pressure, total serum cholesterol, and diagnosed diabetes [2, 3,
25]. DPPs associated to an absolute change in each risk factor between 2000 and 2012 were
calculated using: a) a regression-based approach for factors measured on a continuous scale
(such as total blood cholesterol, systolic blood pressure and BMI) or b) a population-attribut-
able risk fraction (PARF) approach to estimate the effect of variations in categorical
variables.
In the case of the regression-based approach, we used sex and age-specific independent
regression coefficients of mortality benefit for a unit change in the mean of each risk factor [2,
3, 25, 40]. In S4 Appendix we listed the sources for the regression (beta) coefficients utilized in
these analyses. We estimated the number of DPPrisk as a result of the change in the mean value
of each of these risk factors considering the product of: the number of deaths from CHD in
2000 (the baseline year), the subsequent change in that risk factor, and the regression coeffi-
cient measuring the variation in mortality from CHD per unit of absolute change in the risk
factor [3, 16, 17].
DPPrisk ¼ ð1  ðEXPðcoefficient�changeÞÞ�deaths in 2000
For example, there were 4,069 CHD deaths in 12,629,000 men aged 65–74 Years in 2000. In
this groups, mean systolic blood pressure reduced by 0.82 mmHg (from 130.4 in 2000 to 129.6
mmHg in 2012) [3, 20, 36, 37]. Previous meta-analyses reported an expected age- and sex-spe-
cific decline in mortality of 50% for every 20 mmHg. decrease, generating a logarithmic coeffi-
cient of –0.035 [3, 20, 36, 37]. The number of DPP was then estimated as:
DPPhypertension ¼ ð1  ðEXPðcoefficient�changeÞÞ�deaths in 2000
DPPhypertension ¼ ð1  EXPð  0:035�0:82ÞÞ�4069 ¼ 115
We repeated this process for every age-sex group and continuous risk factor considered.
We applied the population-attributable risk fraction (PARF) approach to estimate the effect
of variations in categorical variables (prevalence of smoking, diabetes, and physical inactivity)
[2, 3, 20, 36]. Sources for the relative risks (RR) utilized in these analyses are listed in the
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S4 Appendix. To estimate the PARF, we applied the following formula [2, 3, 25]:
PARF ¼
P � ðRR   1Þ
1þ P � ðRR   1Þ
Where P is the risk factor prevalence, and RR is a relative risk. We then estimated DPP as
the CHD deaths in 2000 multiplied by the difference in the PARF during the period (2000–
2012).
DPPrisk ¼ CHDdeaths2000�ðPARF2012  PARF2000Þ
For example, suppose that the prevalence of diabetes among men aged 65–74 years was
14.5% in 2000 and 20.7% in 2012. Assuming a RR = 1.93, the PARF in 2000 was 0.119 and
0.161 in 2010. The number of CHD deaths is 2000 was 123,055. The DPP attributable to the
change in diabetes prevalence was therefore:
DPPdiabetes ¼ ð123; 055Þ�ð0:161   0:119Þ ¼ 5; 168
This calculation was then repeated for each sex-age group and for every categorical risk fac-
tor. Finally, we obtained a total DPPrisk for each sex-age group by adding the DPP obtained for
each risk factor across all risk factors. As independent coefficients of regression and relative
risks were derived from multivariate analyses for each risk factor, we assumed that there was
no further overlap across all risk factors considered [2, 3, 25].
Uncertainty analysis
Using Monte Carlo simulation, we computed 95% uncertainty intervals around the model out-
put [2, 3, 25]. To obtain these calculations, we replaced all fixed input parameters used in the
model by suitable probability distributions and then we repeatedly recalculate the model out-
put with values sampled from the given input distributions (S5 Appendix) [2, 3, 25]. We used
the Excel add-in Ersatz software (www.epigear.com) to do 1,000 runs to determine the 95%
uncertainty intervals of the DPP (2.5th and 97.5th centile values corresponding to the lower
and upper limits) [2, 3, 25].
Results
In Mexico between 2000 and 2012, CHD crude mortality rates increased by 33.8% in men and
by 22.8% in women (from 105 to 140 and from 81 to 100 per 100,000 men and women, respec-
tively). In 2012, we observed an excess of 9,370 CHD deaths, compared to those expected from
baseline mortality rates in 2000 (Table 1).
An excess of approximately 10,580 CHD deaths was attributable to changes in major car-
diovascular risk factors (UI -12,273; -9,213 Table 2). Improvements in medical and surgical
treatments together prevented or postponed approximately 3,900 deaths by 2012 (UI 1829;
5950; Table 3). After subtracting the prevented or postponed deaths from the excess of deaths
related to risk factors, an increase of 6624 deaths were obtained, which represent 71% of the
total CHD mortality rise in the study period. The biggest contributor to CHD mortality was
the increase in diabetes prevalence (from 7.7% to 10.7%), which led to an estimated 3,565 addi-
tional CHD deaths (UI 2864; 4271) (Fig 1). The second-largest contribution came from physi-
cal inactivity (from a prevalence of 9% to 19%), which led to an estimated 3,395 additional
deaths (UI 2,775; 4,499). Increases in total cholesterol, mean BMI, and systolic blood pressure
resulted in an estimated additional 2219, 1699 and 1134 deaths, respectively. The only risk fac-
tor that improved was the prevalence of smoking, which decreased by 0.03 percent points and
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prevented 651 deaths (UI 102; 1486). Some risk differences between men and women are
important; women had larger increases in diabetes, smoking and cholesterol, while men had
larger increases in systolic blood pressure and physical inactivity. Although women experi-
enced a larger increase in smoking prevalence, the prevalence for men remained higher.
Medical and surgical treatments together prevented or postponed approximately 3,950
deaths by 2012 (UI 1829; 5950). The largest mortality reductions came from secondary preven-
tion treatments following MI, which prevented or postponed 1,045 deaths (11.2%), mostly due
to statin use increases (Table 3). Approximately 820 deaths (5.6%) were prevented by improve-
ments in the treatment of heart failure in the community (particularly acetylsalicylic acid and
spironolactone), and 605 (6.4%) were attributable to primary prevention (statins and anti-
hypertensives). Treatment of angina pectoris in the community prevented 532 deaths (5.7%),
largely attributable to revascularization, which prevented 3.8% deaths as compared with deaths
in the year 2000. Improvements in acute phase management (MI and unstable angina) were
modest and prevented approximately 306 deaths (3.3%)
The relative contribution of new therapies and improvements in the risk factor to the over-
all decrease in CHD deaths in 2012 was consistent through sensitivity analyses (Fig 1). The
largest part of the mortality increase was explained by large rises in diabetes, physical inactiv-
ity, and total cholesterol. Likewise, mortality reductions were linked to lower smoking preva-
lence and an increase in therapies for secondary prevention following MI and heart failure
treatment in the community.
Table 1. Population sizes and death rates due to CHD in Mexico, 2000 and 2012.
Sex and age
group













8’063,423 351 4.4 8,813,802 668 7.6 383.7 284
25–
44
5’812,452 1006 17.3 7,651,545 1623 21.2 1324.3 299
45–
54
3’861,354 2246 58.2 5,682,366 3660 64.4 3305.2 355
55–
64
2’490,327 4069 163.4 3,699,270 6320 170.8 6044.3 276
65–
74
1’556,271 5857 376.3 2,105,313 8930 424.2 7923.3 1007
75–
84
691,352 5879 850.4 1,021,032 10578 1,036.0 8682.5 1896
85+ 208,240 4480 2151.4 322,970 9500 2,941.4 6948.3 2552
Female 25–
34
8’496,491 137 1.6 9,657,083 186 1.9 155.7 30
25–
44
6’178,879 379 6.1 8,463,679 560 6.6 519.1 41
45–
54
4’103,677 926 22.6 6,287,850 1401 22.3 1418.9 -18
55–
64
2’669,170 2279 85.4 4,095,052 2943 71.9 3496.5 -553
65–
74
1’687,604 4257 252.3 2,390,205 5662 236.9 6029.3 -367
75–
84
800,691 5583 697.3 1,223,432 9443 771.8 8530.7 912
85+ 279,845 6290 2247.7 441,089 12572 2,850.2 9914.2 2658
GAP TO EXPLAIN 9370
https://doi.org/10.1371/journal.pone.0242930.t001
PLOS ONE Explaining the increment in coronary heart disease mortality in Mexico between 2000 and 2012
PLOS ONE | https://doi.org/10.1371/journal.pone.0242930 December 3, 2020 7 / 15
Discussion
We aimed to estimate the contribution of changes in risk factors and treatments to CHD mor-
tality increases in Mexico. We found that CHD crude mortality rates increased substantially
between 2000 and 2012 (33.8% in men and 22.8% in women). This mortality increase was
attributable to adverse trends in major risk factors, mainly diabetes, cholesterol, and physical
inactivity. Mortality rises were mitigated by medical interventions, which prevented or post-
poned approximately 3900 deaths, potentially decreasing overall CHD mortality by about
40%.
Most of the previous IMPACT models were implemented in high income countries that are
experiencing a decrease in CHD mortality, mostly attributable to risk factor reductions [3, 17,
20, 36, 40]. Those are the cases of United Kingdom, Denmark, Japan, Netherlands or the
United States, among others [3, 20, 25, 35, 40]. In Latin America, only Argentina has imple-
mented the IMPACT model and, while they have experienced some increases in diabetes and
obesity, the improvements in medical treatments and positive changes in cholesterol and
blood pressure resulted in a net 29.8% reduction in deaths from 1995 to 2010 [15]. Mexico is
Table 2. Deaths from coronary heart disease that were prevented or postponed as a result of changes in population risk factors in Mexico from 2000 to 2012.
Risk factor Risk factor
level
Risk factor change Deaths prevented or postponed
2000 2012 Absolute Relative Best estimate Minimun estimate Maximum estimate Best estimate Minimun estimate Maximum estimate
No. Deaths % of total change
SYSTOLIC BLOOD PRESSURE
(mmHg)
All 124.1 123.2 0.94 0.01 - 1,137.3 - 1,686.4 - 704.8 12.1% 7.5% 18.3%
Men 125.3 124.6 0.71 0.01 - 1,251.8 - 1,736.8 - 857.5 13.4% 9.2% 18.4%
Women 123.0 121.9 1.14 0.01 114.5 77.0 156.2 -1.2% -1.7% -0.8%
CHOLESTEROL (mmol/
L)
All 4.9 5.1 (0.19) (0.04) - 2,203.0 - 3,942.7 - 907.6 24% 10% 43%
Men 4.9 4.9 - - - - - 0% 0% 0%
Women 5.0 5.3 (0.35) (0.07) - 2,203.0 - 3,837.0 - 626.8 24% 7% 40%
BMI (Kg/ m2)
All 26.4 28.6 (2.24) (0.08) - 1,692.6 - 2,086.5 - 1,261.5 18% 13% 23%
Men 25.8 28.0 (2.23) (0.09) - 944.0 - 1,228.6 - 666.9 10% 7% 13%
Women 27.0 29.2 (2.24) (0.08) - 748.5 - 1,085.8 - 415.8 8% 4% 12%
SMOKING (%)
All 0.22 0.19 0.03 0.10 649.6 - 102.6 1,482.6 -7% -16% 1%
Men 0.35 0.30 0.04 0.13 532.6 9.0 988.0 -6% -10% 0%
Women 0.11 0.10 0.01 0.07 116.9 - 427.8 643.3 -1% -7% 5%
PHYSICAL
INACTIVITY (%)
All 0.11 0.18 (0.08) (0.75) - 2,609.1 - 3,129.3 - 2,045.2 28% 22% 33%
Men 0.10 0.19 (0.09) (0.95) - 1,500.5 - 1,852.7 - 1,140.9 16% 12% 20%
Women 0.11 0.18 (0.06) (0.58) - 1,108.7 - 1,473.2 - 637.1 12% 7% 16%
DIABETES (%)
All 0.06 0.09 (0.04) (0.58) - 4,041.6 - 4,842.9 - 3,247.6 43% 35% 51%
Men 0.05 0.09 (0.03) (0.48) - 1,681.1 - 1,270.1 - 2,301.8 18% 14% 25%
Women 0.06 0.10 (0.04) (0.67) - 2,360.5 - 1,761.5 - 2,976.0 25% 19% 32%
TOTAL RISK
FACTORS
-11,034.1 - 12,796.9 - 9,605.7 118% 102% 138%
https://doi.org/10.1371/journal.pone.0242930.t002
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Table 3. Estimated deaths prevented or postponed by medical or surgical treatments in Mexico 2012.




















No. Deaths % of total change
Myocardial infarction
Aspirin 17,516 0.92 0.03 47 -13 102 -0.5% -1.1% 0.1%
ACE inhibitor 17,516 0.62 0.01 38 27 53 -0.4% -0.6% -0.3%
Beta blockers 17,516 0.66 0.01 31 21 41 -0.3% -0.4% -0.2%
CABG 17,516 0.02 0.06 -2 -7 2 0.0% 0.0% 0.1%
PTCA (STEMI) 7,006 0.25 0.04 30 8 47 -0.3% -0.5% -0.1%
Hospital CPR 518 0.63 0.05 10 -613 504 -0.1% -0.3% 0.0%
Thrombolysis 17,516 0.43 0.04 81 -10 190 -0.9% -2.1% 0.1%
PTCA (NSTEMI) 10,510 0.25 0.05 48 -1 79 -0.5% -0.8% 0.0%
Clopidrogel 17,516 0.90 0.00 40 -40 25 -0.4% 0.4% -0.3%
Total 324 212 421 -3.5% -4.5% -2.3%
Unstable angina
Aspirin 13,553 0.92 0.01 13 -29 54 -0.1% -0.6% 0.3%
Aspirin & Heparin 13,553 0.59 0.02 74 -8 173 -0.8% -1.8% 0.1%
ACE inhibitor 13,553 0.55 0.00 10 -24 44 -0.1% -0.5% 0.2%
Beta blockers 13,553 0.66 0.00 14 -32 60 -0.2% -0.6% 0.3%
CABG 13,553 0.07 0.03 5 61 -58 0.0% 0.6% -0.6%
PTCA (STEMI) 13,553 0.38 0.02 33 -4 85 -0.4% -0.9% 0.0%
Total 148 -7 319 -1.6% -3.4% 0.1%
Secondary prevention following myocardial infarction
Statins 5,073,162 0.23 0.01 424 281 674 -4.5% -7.1% -2.9%
Aspirin 5,073,162 0.75 0.00 10 14 6 -0.1% -0.1% -0.2%
Warfarin 5,073,162 0.00 0.01 -77 -216 34 0.8% -0.4% 2.3%
ACE inhibitor 5,073,162 0.25 0.01 218 -939 1102 -2.3% -11.7% 10.1%
Beta blockers 5,073,162 0.27 0.01 148 1000 -830 -1.6% 9.0% -10.7%
Rehabilitation 5,073,162 0.03 0.01 214 -1096 1706 -2.3% -18.4% 11.6%
Total 936 -2851 4474 -10.0% -47.8% 29.6%
Secondary prevention following CABG o PTCA
Statins 118,572 0.62 0.01 80 135 31 -0.9% -0.3% -1.5%
Aspirin 118,572 0.83 0.01 101 261 -13 -1.1% 0.1% -2.8%
Warfarin 118,572 0.00 0.01 -2 -4 0 0.0% 0.0% 0.0%
ACE inhibitor 118,572 0.34 0.01 63 17 97 -0.7% -1.0% -0.2%
Beta blockers 118,572 0.33 0.01 42 9 73 -0.5% -0.8% -0.1%
Rehabilitation 118,572 0.04 0.01 13 -39 73 -0.1% -0.8% 0.4%
Total 298 -129 652 -3.2% -7.0% 1.4%
Chronic angina
Statins 742,011 0.30 0.01 58 -25 141 -0.6% -1.5% 0.3%
Aspirin 742,011 0.46 0.00 108 9 227 -1.2% -2.4% -0.1%
CABG 742,011 0.05 0.01 348 129 751 -3.7% -8.0% -1.4%
Total 514 248 845 -5.5% -9.1% -2.7%
Heart failure with hospital admission
Aspirin 22,539 0.44 0.05 120 52 200 -1.3% -2.1% -0.5%
ACE inhibitor 22,539 0.24 0.06 82 42 116 -0.9% -1.3% -0.5%
Beta blockers 22,539 0.22 0.11 118 41 185 -1.3% -2.0% -0.4%
(Continued)
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one of the few countries in Latin America that still experiences an upward trend for CHD mor-
tality [5, 14]. In the case of countries or regions experiencing upwards trends, IMPACT models
were previously implemented in Beijing, Tunisia and Syria; in those cases, risk factors were the
main contributors to the increases in CHD mortality [16, 18, 23]. Cholesterol was the primary
driver of CHD mortality in Beijing and Tunisia, while blood pressure was the main driver in
Syria [16, 18, 23].
In our study, CHD excess mortality was mainly explained through increases in risk factors,
mostly changes in diabetes, cholesterol and physical inactivity. These changes occurred along
with rapid urbanization and changes in dietary patterns, leading to more physical inactivity
and a transition from traditional to Westernised ultra-processed diet [41–45]. These changes
in behavioral lifestyles have been associated with an increase in diabetes, obesity and hypercho-
lesterolemia [16, 23, 45, 46]. In our analysis, diabetes was the main contributor to the increase
Table 3. (Continued)




















No. Deaths % of total change
Spironolactone 22,539 0.24 0.09 130 74 177 -1.4% -1.9% -0.8%
Total 450 341 588 -4.8% -6.3% -3.6%
Heart failure in the community
Aspirin 985,831 0.60 0.01 108 72 147 -1.2% -1.6% -0.8%
ACE inhibitor 985,831 0.21 0.02 163 -34 360 -1.7% -3.8% 0.4%
Beta blockers 985,831 0.18 0.03 140 34 290 -1.5% -3.1% -0.4%
Spironolactone 985,831 0.08 0.03 90 50 158 -1.0% -1.7% -0.5%
Total 501 320 714 -5.3% -7.8% -3.4%
Statins for primary
prevention
9,853,600 0.23 0.00 114 68 192 -1.2% -2.0% -0.7%
Anti-hypertensive
medication
11,413,962 0.20 0.00 490 -148 963 -5.2% -10.3% 1.6%
Total treatments 3776 1744 5675 -40.3% -61.4% -18.1%
CABG indicates coronary artery bypass graft; PTCA Percutaneous transluminal coronary angioplasty; HF heart failure, AH antihypertensive and PCI percutaneous
coronary intervention.
https://doi.org/10.1371/journal.pone.0242930.t003
Fig 1. Proportion of all coronary heart disease deaths explained by the model, which were attributed to the
contribution of treatments and risk factors in Mexico, 2000 to 2012. The bars are the best model estimate and the
vertical lines the extreme minimum and maximum estimates in sensitivity analysis. CABG indicates coronary artery
bypass graft; PTCA Percutaneous transluminal coronary angioplasty; HF heart failure, AH antihypertensive and PCI
percutaneous coronary intervention.
https://doi.org/10.1371/journal.pone.0242930.g001
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in CHD mortality, given that its self-reported prevalence increased from 5.7% in 2000 to 9.2%
in 2012 [47, 48]. The fact that these risk factors share the same fundamental causes, points at
the opportunities to implement population-based interventions to provide healthier contexts
for diet and physical activity [22]. Over the past decade, Mexico has developed a clear agenda
to reduce obesity and metabolic diseases, based on population interventions, such as taxes to
unhealthy foods and food warning labels [41, 42]. However, further population-based policies
efforts will be needed to reduce obesity, diabetes and CHD deaths in Mexico.
Smoking prevalence fell by 3%, preventing or postponing approximately 670 deaths. How-
ever, in the Latin American region, Mexico was one of the first countries to join the Frame-
work Convention on Tobacco Control (FCTC) and has implemented policy changes to reduce
tobacco consumption [49]. Main actions included: cigarette taxes increased from 40% in 2002
to 55% of the total price by 2011, national and local smoke-free air laws were implemented,
restrictions on tobacco product marketing were strengthened, and prominent pictorial health
warnings were required on cigarette packs [49]. However, bigger falls have won large falls in
CHD mortality in countries such as the USA, England, and Portugal [2, 3, 19]. Mexico there-
fore needs to further increase compliance with key tobacco regulations and strengthen the
tobacco control regulatory framework to further reduce the smoking prevalence and tobacco-
related CHD deaths [49].
Around 2000 and 2012, medical and surgical procedures prevented or postponed nearly
3,900 deaths. The most important contributions came from post-MI secondary treatment, angina
treatment and heart failure in the community. Cardiac rehabilitation units in Mexico, increased
from 10 in 2009 to 24 in 2015, [50]. However, coverage is still very low, only 4.4% of eligible
patients are referred to rehabilitation programs [50]. This is reassuringly consistent with IMPACT
model analyses in high-income countries with decreasing CHD mortality [2, 3, 18, 21]. In Syria,
the main contribution was from chronic angina treatment [23], from hypertension treatment and
myocardial infarction in Beijing [16], and from secondary prevention after MI and hypertension
management in Tunisia [18]. This highlights the Rose Principle that the numerically biggest bene-
fits will come from applying effective interventions to the largest patient groups.
Although heart failure therapies in the community had the second-largest contribution to
deaths prevented or postponed, previous studies in Mexico suggest that the doses of angioten-
sin convert enzyme (ACE), spironolactone, and beta-blockers are not optimal [51, 52]. Revas-
cularization from CABG and PTCA together prevented barely 300 deaths, 4% of total CHD
deaths, a similar proportion to that observed in Turkey, USA and England, and Wales [2, 3,
16, 24]. Previous studies from the OECD estimated that Mexico has the lowest number of
PTCA in the organization [53, 54].
All CHD models have limitations and are dependent on the quality and extent of data avail-
able. We made the best efforts to include the most representative and unbiased data available
in Mexico. We performed a review to critically summarize the evidence from surveys, regis-
tries, and studies that quantified the distribution and frequency of all risk factors included in
this model and of most treatment uptakes. Mexican cholesterol data from the National Health
and Nutrition Surveys were lacking, we therefore extrapolated information from the Global
Burden of Disease (GBD) study [55]. Furthermore, it was not possible to obtain precise data
on treatment uptake in Mexico for heart failure and chronic angina treatments. We therefore
strengthened our assumptions by obtaining estimates from a consensus group of experts who
critically evaluated all the available evidence. The IMPACT model explained 71% of CHD
mortality increases; yet, 29% remained unexplained and might reflect data limitations or other
unmeasured factors. Finally, we also assumed that the efficiency of therapies in randomized
controlled trials could be generalized to population effectiveness in normal clinical practice [3,
22, 36], which could lead to an overestimation of the net benefit of medical interventions.
PLOS ONE Explaining the increment in coronary heart disease mortality in Mexico between 2000 and 2012
PLOS ONE | https://doi.org/10.1371/journal.pone.0242930 December 3, 2020 11 / 15
Conclusions
Coronary heart disease mortality in Mexico is increasing due to adverse trends in major risk
factors and suboptimal use of CHD treatments. Preventive efforts made so far have failed to
achieve a substantial impact. Future public policies will therefore need to focus on incentiviz-
ing physical activity, strengthening tobacco control policies, promoting healthy foods and dis-
couraging the consumption of processed foods and sugary drinks. Medical and surgical
advances have helped to reduce the mortality burden in Mexico; however, their access remains
limited and restricted to higher socioeconomic groups. As the country moves to increase cov-
erage for the population [56], an equitable distribution of resources will also be crucial.
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